Multi-omics analysis identifies PTTG1 as a prognostic biomarker associated with immunotherapy and chemotherapy resistance
PTTG1 shows potential as a cancer diagnostic, prognostic, and chemosensitivity marker. Increased PTTG1 expression is linked to resistance to cancer treatment. The mechanism could be linked to PTTG1's role in promoting cytotoxic T lymphocyte dysfunction and mediating T cell exhaustion. It is feasible to consider PTTG1, which is expressed on Treg and Tprolif cells, as a new therapeutic target for overcoming immunotherapy resistance.
Authors
- Chunlin Zou (ORCID: https://orcid.org/0000-0002-3308-5544)
- Shuxing Chen (ORCID: https://orcid.org/0000-0002-5546-342X)
- Handong Wei
- Yaxin Ma
- Lihui Wang
Institutions
- Guangxi University (CN)
- Guangxi Medical University (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2024-10-25
- DOI
- https://doi.org/10.1186/s12885-024-13060-5
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- National Natural Science Foundation of China
- National College Students Innovation and Entrepreneurship Training Program